ALNY

Analyst Note: ALNY (Alnylam Pharmaceuticals, Inc.)

Date: 2026-06-13 Sector: Healthcare / Biotechnology

1. Structural Readiness

Current State: INVALIDATED

• Conservative Entry: None (Setup is invalidated).
• Aggressive Entry: $341.63 (This level is now obsolete as the structure has broken; a re-test of this level would be required to re-establish a forming coil, but currently, the setup is closed).
• Breakout Level: $495.55 (The resistance level that must be cleared for a new confirmed breakout, currently irrelevant until the structure reforms).
• Extension: — (No extension data available as the setup is not active).

Classification: The coil is INVALIDATED.

2. Thesis Layer

Primary Secular Theme: Biotech & GLP-1 → Rare & Orphan (Tier Direct, High Confidence) Secondary Exposure: Cardiovascular / Metabolic (via RNAi platform expansion)

ALNY is a direct beneficiary of the secular thesis surrounding Rare & Orphan diseases, specifically within the Transthyretin (TTR) amyloidosis space. The company's role is that of a primary innovator and commercial leader in RNAi therapeutics.

• Thesis Strength: The company is not merely a participant but the architect of the TTR treatment landscape. The evidence indicates a "tier direct" exposure where the company's core revenue drivers (AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO) are directly aligned with the unmet medical needs in rare genetic disorders.
• Additional Tailwinds: The company is also leveraging the "Cardiovascular" secular wave through its pipeline (e.g., zilebesiran for hypertension, AMVUTTRA for ATTR-CM). While the primary thesis is Rare & Orphan, the expansion into broad cardiovascular indications (hypertension, heart failure) provides a secondary layer of secular growth that differentiates ALNY from pure-play orphan drug companies.

3. Business Analysis

Business Model: Alnylam Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The business model relies on a dual engine:

• Direct Commercialization: Selling proprietary siRNA drugs (e.g., AMVUTTRA, ONPATTRO) to patients and payers.
• Strategic Collaborations: Licensing and royalty arrangements with partners (e.g., Roche for Leqvio/Qfitlia).

Operational Status (as of 2026-06-13):

• Revenue Growth: The company reported robust top-line growth in Q1 2026. Global TTR net revenues reached $910 million, a 153% year-over-year increase and a 6% sequential increase from Q4 2025. Combined net product revenues were $1.036 billion, up 121% year-over-year.
• Product Portfolio: As of March 31, 2026, the company generates worldwide product revenues from four commercialized products: AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO. Additionally, the company has six marketed medicines in total, including two commercialized by collaborators.
• Pipeline & Strategy: The company is executing its "Alnylam 2030" strategy, launched in early 2026. Key developments include:
• AMVUTTRA: Approved in March 2025 for the treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) to reduce cardiovascular mortality and hospitalizations.
• Nucresiran: Phase 3 trials (TRITON-PN and TRITON-CM) initiated in late 2025 for hATTR polyneuropathy and ATTR amyloidosis with cardiomyopathy.
• Zilebesiran: Phase 3 cardiovascular outcomes trial (ZENITH) initiated in September 2025 for uncontrolled hypertension.
• Financial Health: Management stated in the Q1 2026 earnings transcript that cash, cash equivalents, marketable securities, and expected revenue (including royalties from Leqvio and Qfitlia) are sufficient to satisfy near-term capital and operating needs for at least the next 12 months.
• Backlog: As of March 31, 2026, the aggregate amount of transaction price allocated to Roche Performance Obligations unsatisfied was $870.0 million, expected to be recognized over the term of the agreement.

4. Archetype and Conviction

Archetype: Quality Compounder Fit: The company fits the "Quality Compounder" archetype due to its sustained double-digit revenue growth, expanding total addressable market (TAM) in rare diseases, and a clear path to profitability with a target non-GAAP operating margin of ~30% by 2030.

Conviction Stack:

• Thesis Strength: High. The company is the dominant player in a high-growth, underdiagnosed therapeutic area (ATTR-CM affects >300,000 people worldwide, with >80% untreated).
• Evidence Quality: Strong. The evidence base (E1–E29) is comprehensive, covering earnings transcripts, SEC filings, and company profiles, all dated prior to or on the event date.
• Valuation Context: The financial spine indicates forward consensus EPS of $7.49 (FY1) and $10.67 (FY2). The current price of $278.09 implies a forward P/E ratio that must be weighed against the 25%+ CAGR guidance.
• ATR Context: The current ATR is 3.6%, which falls within the "productive" range (historically 4–6% is the sweet spot, but 3.6% indicates moderate volatility). This suggests the stock is not in a "severe loser" extreme (>8%) but is experiencing normal trading volatility. However, the invalidation of the coil structure overrides the ATR signal for entry purposes.

Summary: The business is a high-quality compounder with strong secular tailwinds and solid financials. However, the technical setup is currently invalid, meaning the structural entry criteria are not met. The "Quality Compounder" thesis is intact, but the "Coil" setup is broken.

5. Invalidations, Strengtheners, and Gaps

What Would Invalidate the Case (Fundamental):

• Failure to meet the 2026 TTR revenue guidance or a significant slowdown in AMVUTTRA uptake.
• Clinical trial failures in the nucresiran or zilebesiran programs (TRITON-PN, TRITON-CM, ZENITH).
• Regulatory delays or rejections for new indications.

What Would Strengthen the Case:

• Successful top-line data readouts from Phase 3 trials (nucresiran, zilebesiran).
• Expansion of AMVUTTRA into new geographies or indications beyond ATTR-CM.

Gaps in Evidence:

• Missing Evidence: No specific data on the *current* quarter's guidance revision or immediate liquidity concerns beyond the 12-month sufficiency statement.

PRIVATE ANALYST CALL

Judgment: Sell Confidence: high Key risks: Technical breakdown may precede fundamental deterioration; Sector rotation in healthcare; Clinical trial delays in late-stage pipeline. Sizing hint: Position size should be zero until structure reforms; do not attempt to catch a falling knife on a invalidated coil. Expected path: Management expects continued revenue growth and pipeline progress; however, the market is currently pricing in a structural break that requires a re-test of support or a new catalyst to reverse. Failure mode to watch: A sustained close below $278.09 with no recovery attempt, indicating a deeper trend change.